CNC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Centene Corp (CNC) is not a strong buy for a beginner investor with a long-term horizon at this time. While the stock shows some positive technical indicators and analyst optimism, the company's recent financial performance is concerning, with significant declines in net income and EPS. Additionally, there are no strong proprietary trading signals or significant catalysts to justify immediate action.
The technical indicators for CNC are moderately positive. The MACD is above zero and positively contracting, indicating bullish momentum. The RSI is neutral at 58.753, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 43.79), suggesting limited immediate upside potential.
Analysts have raised price targets recently, with some firms maintaining a Buy or Outperform rating, indicating optimism about margin recovery and Medicare Advantage opportunities.
Centene's investments in social services and healthcare access demonstrate a commitment to long-term growth and community impact.
Financial performance in Q4 2025 was weak, with a significant drop in net income (-489.05% YoY) and EPS (-500.00% YoY).
Concerns over Medicaid and exchange visibility in 2026, as highlighted by analysts, could weigh on the stock's performance.
No significant insider or hedge fund activity, and no recent Congress trading data to indicate confidence from influential stakeholders.
In Q4 2025, Centene's revenue increased by 21.86% YoY to $49.73 billion. However, net income dropped significantly to -$1.1 billion (-489.05% YoY), and EPS fell to -2.24 (-500.00% YoY). Gross margin also declined to 4.3% (-48.50% YoY), reflecting operational challenges.
Analyst sentiment is mixed but leans slightly positive. Recent upgrades and raised price targets (e.g., Truist to $49, Barclays to $54) reflect optimism about margin recovery and Medicare Advantage opportunities. However, some analysts express concerns about Medicaid and exchange visibility in 2026, leading to cautious ratings like Hold or Neutral from firms such as Deutsche Bank and Mizuho.
